Evommune, Inc. (NYSE:EVMN) Receives Average Rating of "Moderate Buy" from Analysts

Key Points

• Analyst consensus: Eleven firms rate Evommune an average of "Moderate Buy" (1 sell, 1 hold, 7 buy, 2 strong buy) with a mean 1-year target of about $49.67.
• Recent results and valuation: Evommune reported a quarterly EPS of ($1.43) vs. consensus ($0.82) (miss), trades around $24.05 with a negative PE (~-2.98) and a 52-week range of $13.89–$33.20.
• Business and institutional interest: The clinical-stage biotech focuses on inflammatory diseases (CSU, atopic dermatitis, ulcerative colitis), and several institutional investors including State Street and Oxford Asset Management recently initiated or added small stakes.

Shares of Evommune, Inc. (NYSE:EVMN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eleven research firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $49.6667.

Several equities analysts have issued reports on the stock. Weiss Ratings began coverage on shares of Evommune in a research report on Tuesday, February 3rd. They issued a "sell (e)" rating for the company. William Blair began coverage on Evommune in a research report on Monday, December 1st. They set an "outperform" rating for the company. Leerink Partners began coverage on Evommune in a report on Monday, December 1st. They set an "outperform" rating and a $42.00 target price on the stock. Cantor Fitzgerald assumed coverage on Evommune in a research note on Monday, December 1st. They issued an "overweight" rating for the company. Finally, Wall Street Zen upgraded Evommune from a "sell" rating to a "hold" rating in a research report on Sunday, December 14th.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in EVMN. China Universal Asset Management Co. Ltd. bought a new stake in shares of Evommune in the 4th quarter valued at $34,000. The Manufacturers Life Insurance Company acquired a new position in Evommune in the fourth quarter valued at $179,000. XTX Topco Ltd bought a new stake in Evommune during the fourth quarter valued at $321,000. Oxford Asset Management LLP bought a new stake in Evommune during the fourth quarter valued at $335,000. Finally, State Street Corp acquired a new stake in Evommune during the 4th quarter worth about $539,000.

Evommune Stock Performance

NYSE:EVMN opened at $24.05 on Wednesday. The business's 50-day moving average price is $22.32. Evommune has a 1-year low of $13.89 and a 1-year high of $33.20. The company has a market capitalization of $866.23 million and a PE ratio of -2.98.

Evommune (NYSE:EVMN - Get Free Report) last issued its quarterly earnings data on Thursday, March 5th. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.61).

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients' quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.